<DOC>
	<DOCNO>NCT00980005</DOCNO>
	<brief_summary>The objective study evaluate immunogenicity safety GSK Biologicals ' investigational vaccine GSK1557482A .</brief_summary>
	<brief_title>Study Assess Immunogenicity Safety Investigational Influenza Vaccine Children</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects and/or subject parent ( ) /Legally Acceptable Representative ( ) ( LAR ) investigator believe comply requirement protocol . A male female child age 3 year 17 year age time first vaccination ; child may may previous administration influenza vaccine previous season acceptable . Written inform consent obtain subject/from parent ( ) /LAR ( ) subject . Healthy subject establish medical history historydirected clinical examination enter study . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Use investigational nonregistered product study vaccine within 30 day precede administration study vaccine , plan use study period . Routine , register childhood vaccination register recommended pandemic influenza vaccine exclusion . Receipt seasonal influenza vaccine outside study , current ( 20092010 ) flu season . Child care Receipt systemic glucocorticoid within 1 month prior study enrollment , cytotoxic immunosuppressive drug within 6 month study enrollment . Topical , intraarticular inhale glucocorticoid allow . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . History hypersensitivity vaccine . History GuillainBarr√©syndrome within 6 week receipt prior inactivate influenza virus vaccine . History reaction hypersensitivity likely exacerbate component vaccine ( ) . Acute disease and/or fever time enrolment . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period . Pregnant lactate female . History chronic alcohol consumption and/or drug abuse . Female plan become pregnant planning discontinue contraceptive precaution . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>GSK Biologicals influenza vaccine GSK1557482A</keyword>
	<keyword>influenza infection</keyword>
</DOC>